{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:31:21Z","timestamp":1791894681197,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-72067-7","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:38:37Z","timestamp":1776706717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Engineered BCG selectively triggers trained immunity in tumor-associated macrophages and sensitizes glioblastoma to radiotherapy in mice"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5317-9820","authenticated-orcid":false,"given":"Ke","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyuan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-7435","authenticated-orcid":false,"given":"Tai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1108-1809","authenticated-orcid":false,"given":"Dahai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0645-1868","authenticated-orcid":false,"given":"Lizhou","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7751-7652","authenticated-orcid":false,"given":"Haishi","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"72067_CR1","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/s43018-023-00619-7","volume":"4","author":"DA Jaffray","year":"2023","unstructured":"Jaffray, D. A., Knaul, F., Baumann, M. & Gospodarowicz, M. Harnessing progress in radiotherapy for global cancer control. Nat. Cancer 4, 1228\u20131238 (2023).","journal-title":"Nat. Cancer"},{"key":"72067_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","volume":"8","author":"S Guo","year":"2023","unstructured":"Guo, S. et al. Radiation-induced tumor immune microenvironments and potential targets for combination therapy. Signal. Transduct. Target. Ther. 8, 205 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"72067_CR3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843\u2013852 (2014).","journal-title":"Immunity"},{"key":"72067_CR4","doi-asserted-by":"publisher","first-page":"8877","DOI":"10.3390\/ijms21228877","volume":"21","author":"Q Storozynsky","year":"2020","unstructured":"Storozynsky, Q. & Hitt, M. M. The impact of radiation-induced DNA damage on cGAS-STING-mediated immune responses to cancer. Int. J. Mol. Sci. 21, 8877 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"72067_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li, K. et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal. Transduct. Target. Ther. 6, 362 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"72067_CR6","doi-asserted-by":"publisher","first-page":"e492","DOI":"10.1016\/j.clon.2021.08.014","volume":"33","author":"MR Horsman","year":"2021","unstructured":"Horsman, M. R., Sorensen, B. S., Busk, M. & Siemann, D. W. Therapeutic modification of hypoxia. Clin. Oncol. 33, e492\u2013e509 (2021).","journal-title":"Clin. Oncol."},{"key":"72067_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1098","volume":"352","author":"MG Netea","year":"2016","unstructured":"Netea, M. G. et al. Trained immunity: a program of innate immune memory in health and disease. Science 352, aaf1098 (2016).","journal-title":"Science"},{"key":"72067_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","volume":"20","author":"MG Netea","year":"2020","unstructured":"Netea, M. G. et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 20, 375\u2013388 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"72067_CR9","doi-asserted-by":"publisher","first-page":"1251086","DOI":"10.1126\/science.1251086","volume":"345","author":"S Saeed","year":"2014","unstructured":"Saeed, S. et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 345, 1251086 (2014).","journal-title":"Science"},{"key":"72067_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41581-022-00633-5","volume":"19","author":"J Ochando","year":"2023","unstructured":"Ochando, J., Mulder, W. J. M., Madsen, J. C., Netea, M. G. & Duivenvoorden, R. Trained immunity - basic concepts and contributions to immunopathology. Nat. Rev. Nephrol. 19, 23\u201337 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"72067_CR11","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.chom.2023.10.015","volume":"31","author":"A Ziogas","year":"2023","unstructured":"Ziogas, A., Bruno, M., van der Meel, R., Mulder, W. J. M. & Netea, M. G. Trained immunity: target for prophylaxis and therapy. Cell Host Microbe 31, 1776\u20131791 (2023).","journal-title":"Cell Host Microbe"},{"key":"72067_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41573-019-0025-4","volume":"18","author":"WJM Mulder","year":"2019","unstructured":"Mulder, W. J. M., Ochando, J., Joosten, L. A. B., Fayad, Z. A. & Netea, M. G. Therapeutic targeting of trained immunity. Nat. Rev. Drug Discov. 18, 553\u2013566 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"72067_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41590-022-01388-8","volume":"24","author":"C Ding","year":"2023","unstructured":"Ding, C. et al. Inducing trained immunity in pro-metastatic macrophages to control tumor metastasis. Nat. Immunol. 24, 239\u2013254 (2023).","journal-title":"Nat. Immunol."},{"key":"72067_CR14","doi-asserted-by":"publisher","first-page":"34219","DOI":"10.1021\/acsnano.4c11658","volume":"18","author":"L Zhang","year":"2024","unstructured":"Zhang, L. et al. Targeted initiation of trained immunity in tumor-associated macrophages with membrane-camouflaged Bacillus Calmette-Guerin for lung carcinoma immunotherapy. ACS Nano 18, 34219\u201334234 (2024).","journal-title":"ACS Nano"},{"key":"72067_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.juro.2015.08.075","volume":"195","author":"A Yokomizo","year":"2016","unstructured":"Yokomizo, A. et al. Randomized controlled study of the efficacy, safety and quality of life with low dose Bacillus Calmette-Guerin instillation therapy for nonmuscle invasive bladder cancer. J. Urol. 195, 41\u201346 (2016).","journal-title":"J. Urol."},{"key":"72067_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","volume":"15","author":"C Pettenati","year":"2018","unstructured":"Pettenati, C. & Ingersoll, M. A. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat. Rev. Urol. 15, 615\u2013625 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"72067_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41585-020-0346-4","volume":"17","author":"JH van Puffelen","year":"2020","unstructured":"van Puffelen, J. H. et al. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nat. Rev. Urol. 17, 513\u2013525 (2020).","journal-title":"Nat. Rev. Urol."},{"key":"72067_CR18","doi-asserted-by":"publisher","first-page":"17537","DOI":"10.1073\/pnas.1202870109","volume":"109","author":"J Kleinnijenhuis","year":"2012","unstructured":"Kleinnijenhuis, J. et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc. Natl. Acad. Sci. USA 109, 17537\u201317542 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"72067_CR19","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1016\/j.celrep.2016.11.011","volume":"17","author":"RJW Arts","year":"2016","unstructured":"Arts, R. J. W. et al. Immunometabolic pathways in BCG-induced trained immunity. Cell Rep. 17, 2562\u20132571 (2016).","journal-title":"Cell Rep."},{"key":"72067_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.immuni.2023.12.005","volume":"57","author":"S Moorlag","year":"2024","unstructured":"Moorlag, S. et al. Multi-omics analysis of innate and adaptive responses to BCG vaccination reveals epigenetic cell states that predict trained immunity. Immunity 57, 171\u2013187.e114 (2024).","journal-title":"Immunity"},{"key":"72067_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-022-00699-x","volume":"20","author":"RH Fang","year":"2023","unstructured":"Fang, R. H., Gao, W. & Zhang, L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat. Rev. Clin. Oncol. 20, 33\u201348 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72067_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202300304","volume":"7","author":"DX Zhang","year":"2024","unstructured":"Zhang, D. X. et al. Biomedical applications of cell membrane-based biomimetic nano-delivery system. Adv. Therapeutics 7, 2300304 (2024).","journal-title":"Adv. Therapeutics"},{"key":"72067_CR23","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1038\/s41401-024-01355-z","volume":"45","author":"YY Zeng","year":"2024","unstructured":"Zeng, Y. Y. et al. Immunocyte membrane-derived biomimetic nano-drug delivery system: a pioneering platform for tumour immunotherapy. Acta Pharmacol. Sin. 45, 2455\u20132473 (2024).","journal-title":"Acta Pharmacol. Sin."},{"key":"72067_CR24","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.1021\/acs.nanolett.2c01863","volume":"22","author":"T Yin","year":"2022","unstructured":"Yin, T. et al. Engineered macrophage-membrane-coated nanoparticles with enhanced PD-1 expression induce immunomodulation for a synergistic and targeted antiglioblastoma activity. Nano Lett. 22, 6606\u20136614 (2022).","journal-title":"Nano Lett."},{"key":"72067_CR25","doi-asserted-by":"publisher","first-page":"132898","DOI":"10.1016\/j.cej.2021.132898","volume":"430","author":"X Huang","year":"2022","unstructured":"Huang, X. et al. Glucose oxidase and L-arginine functionalized black phosphorus nanosheets for multimodal targeted therapy of glioblastoma. Chem. Eng. J. 430, 132898 (2022).","journal-title":"Chem. Eng. J."},{"key":"72067_CR26","doi-asserted-by":"publisher","first-page":"26285","DOI":"10.1021\/acsami.3c01559","volume":"15","author":"Y Ye","year":"2023","unstructured":"Ye, Y. et al. Mitochondria-targeting pyroptosis amplifier of lonidamine-modified black phosphorus nanosheets for glioblastoma treatments. ACS Appl. Mater. Interfaces 15, 26285\u201326297 (2023).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"72067_CR27","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/neuonc\/noac253","volume":"25","author":"JA Dean","year":"2023","unstructured":"Dean, J. A. et al. Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity. Neuro. Oncol. 25, 1100\u20131112 (2023).","journal-title":"Neuro. Oncol."},{"key":"72067_CR28","doi-asserted-by":"publisher","first-page":"e770","DOI":"10.1259\/bjr\/83827377","volume":"85","author":"M Hingorani","year":"2012","unstructured":"Hingorani, M., Colley, W. P., Dixit, S. & Beavis, A. M. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future?. Br. J. Radiol. 85, e770\u2013e781 (2012).","journal-title":"Br. J. Radiol."},{"key":"72067_CR29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z., Liu, X., Chen, D. & Yu, J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal. Transduct. Target. Ther. 7, 258 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"72067_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera, F. G. et al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 12, 108\u2013133 (2022).","journal-title":"Cancer Discov."},{"key":"72067_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh4050","volume":"8","author":"T Walle","year":"2022","unstructured":"Walle, T. et al. Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. Sci. Adv. 8, eabh4050 (2022).","journal-title":"Sci. Adv."},{"key":"72067_CR32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41577-021-00568-1","volume":"22","author":"UM Cytlak","year":"2022","unstructured":"Cytlak, U. M. et al. Immunomodulation by radiotherapy in tumour control and normal tissue toxicity. Nat. Rev. Immunol. 22, 124\u2013138 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"72067_CR33","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1039\/D1BM00112D","volume":"9","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Cisplatin nanoparticles boost abscopal effect of radiation plus anti-PD1 therapy. Biomater. Sci. 9, 3019\u20133027 (2021).","journal-title":"Biomater. Sci."},{"key":"72067_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30543-w","volume":"13","author":"X Guan","year":"2022","unstructured":"Guan, X. et al. Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis. Nat. Commun. 13, 2834 (2022).","journal-title":"Nat. Commun."},{"key":"72067_CR35","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti, S. C. et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat. Med. 24, 1845\u20131851 (2018).","journal-title":"Nat. Med."},{"key":"72067_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223\u2013249 (2021).","journal-title":"Annu. Rev. Pathol."},{"key":"72067_CR37","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-024-00908-9","volume":"21","author":"SY Kwon","year":"2024","unstructured":"Kwon, S. Y., Thi-Thu Ngo, H., Son, J., Hong, Y. & Min, J. J. Exploiting bacteria for cancer immunotherapy. Nat. Rev. Clin. Oncol. 21, 569\u2013589 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72067_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03944-8","volume":"21","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. BCG-induced trained immunity: history, mechanisms and potential applications. J. Transl. Med. 21, 106 (2023).","journal-title":"J. Transl. Med."},{"key":"72067_CR39","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","volume":"23","author":"A Christofides","year":"2022","unstructured":"Christofides, A. et al. The complex role of tumor-infiltrating macrophages. Nat. Immunol. 23, 1148\u20131156 (2022).","journal-title":"Nat. Immunol."},{"key":"72067_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49885-8","volume":"15","author":"A Coulton","year":"2024","unstructured":"Coulton, A. et al. Using a pan-cancer atlas to investigate tumour associated macrophages as regulators of immunotherapy response. Nat. Commun. 15, 5665 (2024).","journal-title":"Nat. Commun."},{"key":"72067_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01645-2","volume":"21","author":"R Bai","year":"2022","unstructured":"Bai, R. et al. The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies. Mol. Cancer 21, 177 (2022).","journal-title":"Mol. Cancer"},{"key":"72067_CR42","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1038\/s41388-023-02869-2","volume":"42","author":"P Fan","year":"2023","unstructured":"Fan, P. et al. Alleviating hypoxia to improve cancer immunotherapy. Oncogene 42, 3591\u20133604 (2023).","journal-title":"Oncogene"},{"key":"72067_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67411-w","volume":"10","author":"VE Sanchez","year":"2020","unstructured":"Sanchez, V. E. et al. GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models. Sci. Rep. 10, 11003 (2020).","journal-title":"Sci. Rep."},{"key":"72067_CR44","first-page":"vdab100","volume":"3","author":"AF Haddad","year":"2021","unstructured":"Haddad, A. F. et al. Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. Neurooncol. Adv. 3, vdab100 (2021).","journal-title":"Neurooncol. Adv."},{"key":"72067_CR45","doi-asserted-by":"publisher","first-page":"1297932","DOI":"10.3389\/fimmu.2023.1297932","volume":"14","author":"JB Iorgulescu","year":"2023","unstructured":"Iorgulescu, J. B. et al. Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model. Front. Immunol. 14, 1297932 (2023).","journal-title":"Front. Immunol."},{"key":"72067_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-107","volume":"12","author":"T Oh","year":"2014","unstructured":"Oh, T. et al. Immunocompetent murine models for the study of glioblastoma immunotherapy. J. Transl. Med. 12, 107 (2014).","journal-title":"J. Transl. Med."},{"key":"72067_CR47","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/2159-8290.CD-19-1355","volume":"10","author":"D Bayik","year":"2020","unstructured":"Bayik, D. et al. Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner. Cancer Discov. 10, 1210\u20131225 (2020).","journal-title":"Cancer Discov."},{"key":"72067_CR48","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.2147\/OTT.S294129","volume":"14","author":"Y Lu","year":"2021","unstructured":"Lu, Y. et al. Remodels the immunosuppressive tumor microenvironment by combination of bacillus Calmette-Guerin and anti-PD-L1 in an orthotopic triple-negative breast cancer mouse model. Onco. Targets Ther. 14, 2247\u20132258 (2021).","journal-title":"Onco. Targets Ther."},{"key":"72067_CR49","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","volume":"147","author":"DL Lamm","year":"1992","unstructured":"Lamm, D. L. et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J. Urol. 147, 596\u2013600 (1992).","journal-title":"J. Urol."},{"key":"72067_CR50","doi-asserted-by":"publisher","first-page":"7738","DOI":"10.1021\/acsnano.6b03148","volume":"10","author":"H Cao","year":"2016","unstructured":"Cao, H. et al. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano 10, 7738\u20137748 (2016).","journal-title":"ACS Nano"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72067-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72067-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72067-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:02:59Z","timestamp":1782086579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72067-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72067"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72067-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5465"}}